AI Investment Is Now Driven by Proof Rather than Promise

Investors, health systems and payers have grown more selective about AI startups in recent years, according to a panel of experts speaking at MedCity News’ INVEST Digital Health conference. Customers and investors alike are now demanding clear evidence of ROI before committing to deals or partnerships. The post AI Investment Is Now Driven by Proof…

Read More

Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug

Saniona’s drug candidate could expand Jazz Pharmaceuticals portfolio in epilepsy. But this preclinical small molecule will need to show advantages in safety and efficacy to compete with Biohaven Pharmaceuticals and Xenon Pharmaceuticals, each with clinical-stage drugs that hit the same epilepsy target. The post Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective…

Read More